Fajar Desi Reski, Rostinawati Tina, Hamijoyo Laniyati, Sahiratmadja Edhyana, Amalia Riezki, Barliana Melisa Intan
Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia.
Institut of Pelamonia Health Sciences, Makassar, Indonesia.
Biologics. 2024 May 3;18:95-106. doi: 10.2147/BTT.S452792. eCollection 2024.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the gene has been found to be linked with SLE events. This study aimed to analyze the association between single nucleotide polymorphisms of the rs9514828 with incidence of atherosclerosis and therapeutic outcomes in patients with SLE.
This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The gene polymorphism was evaluated using polymerase chain reaction followed by sequencing. The lupus low disease activity state (LLDAS) criteria were used to measure the therapeutic outcomes. Statistical analysis was conducted using binary logistic regression.
The genetic variations of rs9514828 were CC = 35, CT = 41, and TT = 8. There was an association between rs9514828 C>T polymorphism in patients with SLE with and without atherosclerosis (p = 0.03; odds ratio (OR) 4.72, 95% confidence interval [CI] 1.22-18.37). Furthermore, the rs9514828 C>T polymorphism had association with the therapeutic outcomes of patients with SLE who manifested with LLDAS (p = 0.00; OR 7.58, 95% CI 2.61-21.99).
The association of rs9514828 C>T polymorphism and incidence of atherosclerosis as well as the therapeutic outcomes in patients with SLE indicate the potential utility of the gene variation as screening tool to employ personalized medicine to undertake preventive measures in order to prevent atherosclerosis and to predict a poor prognosis in SLE patient.
系统性红斑狼疮（SLE）是一种具有众多临床表现的复杂自身免疫性疾病。器官受累会加重SLE患者病情，并引发动脉粥样硬化等合并症。最近，发现该基因与SLE事件有关。本研究旨在分析rs9514828单核苷酸多态性与SLE患者动脉粥样硬化发生率及治疗结果之间的关联。
本病例对照研究纳入84例SLE患者，其中21例患有动脉粥样硬化的SLE患者和63例无动脉粥样硬化的SLE患者。采用酶联免疫吸附测定法对白细胞介素-6和干扰素γ水平进行定量。采用聚合酶链反应随后测序的方法评估该基因多态性。使用狼疮低疾病活动状态（LLDAS）标准来衡量治疗结果。采用二元逻辑回归进行统计分析。
rs9514828的基因变异为CC = 35、CT = 41和TT = 8。患有和未患有动脉粥样硬化的SLE患者中rs9514828 C>T多态性之间存在关联（p = 0.03；比值比[OR] 4.72，95%置信区间[CI] 1.22 - 18.37）。此外，rs9514828 C>T多态性与表现为LLDAS的SLE患者的治疗结果有关（p = 0.00；OR 7.58，95% CI 2.61 - 21.99）。
rs9514828 C>T多态性与SLE患者动脉粥样硬化发生率及治疗结果之间的关联表明，该基因变异作为一种筛查工具具有潜在效用，可用于采用个性化医疗措施预防动脉粥样硬化并预测SLE患者的不良预后。
